<DOC>
	<DOCNO>NCT00640562</DOCNO>
	<brief_summary>Aim study assess new compound Seroquel XR™ non-inferior Risperidone , consider reference drug treatment depressive symptom schizophrenia . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Quetiapine Extended Release Depression Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Provision write informed consent Patients satisfy criterion diagnosis schizophrenia schizoaffective disorder accord DSMIVTR Baseline depressive symptom , assess mean HAMD ( 21item ) score ≥20 , HAMD item 1 score ≥2 Any DSMIV Axis I disorder schizophrenia schizoaffective disorder Patients treat depot antipsychotic medication within 1 dose interval day 0 ; patient treat AP oral medication trial except switch period Use Clozapine within 28 day prior enrollment Clozapine non responder Any significant clinical disorder , opinion investigator , make subject unsuitable give treatment investigational drug An absolute neutrophil count ( ANC ) ≤1.5 x 109 per liter Patients , opinion investigator , pose imminent risk suicide danger self others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Depression</keyword>
	<keyword>Quetiapine</keyword>
</DOC>